Locus Biosciences

Locus Biosciences is a biotechnology company that specializes in the development of CRISPR-Cas system-based bacteriophage therapies. The company was founded in 2015 and is headquartered in Research Triangle Park, North Carolina, United States.

Overview

Locus Biosciences is a leader in the field of CRISPR-based bacteriophage therapeutics. The company's primary focus is on the development of precision antibacterial therapies that can combat antibiotic-resistant bacterial infections. Locus Biosciences uses a unique approach that combines bacteriophages with the CRISPR-Cas system to specifically target and kill pathogenic bacteria while leaving the beneficial bacteria unharmed.

Technology

The technology used by Locus Biosciences is based on the CRISPR-Cas3 system, which is different from the more commonly known CRISPR-Cas9 system. While the CRISPR-Cas9 system is used for gene editing, the CRISPR-Cas3 system is used by Locus Biosciences for its ability to cause DNA degradation in targeted bacteria, effectively killing them.

Products

Locus Biosciences is developing a pipeline of products that target various pathogenic bacteria. These include therapies for urinary tract infections, Clostridium difficile infections, and Pseudomonas aeruginosa infections, among others.

Partnerships

Locus Biosciences has entered into several strategic partnerships to advance its technology and product development. These include partnerships with Janssen Pharmaceuticals, a division of Johnson & Johnson, and the Bill & Melinda Gates Foundation.

See also

• CRISPR
• Bacteriophage
• Antibiotic resistance

References

<references />

External links

• Official website

This article is a stub related to pharmacology. You can help WikiMD by expanding it!